Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management.

Elazezy M, Joosse SA.

Comput Struct Biotechnol J. 2018 Oct 9;16:370-378. doi: 10.1016/j.csbj.2018.10.002. eCollection 2018. Review.

2.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
3.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

PMID:
30030273
4.

Correlation of Isotope Count With Sentinel Node Positivity in Vulvar Cancer.

Woelber L, Joosse SA, Grimm D, Mathey S, Mahner S, Burandt E, Klutmann S, Schmalfeldt B, Prieske K.

Int J Gynecol Cancer. 2018 Sep;28(7):1403-1409. doi: 10.1097/IGC.0000000000001298.

PMID:
29923853
5.

Prenatal Administration of Betamethasone Causes Changes in the T Cell Receptor Repertoire Influencing Development of Autoimmunity.

Gieras A, Gehbauer C, Perna-Barrull D, Engler JB, Diepenbruck I, Glau L, Joosse SA, Kersten N, Klinge S, Mittrücker HW, Friese MA, Vives-Pi M, Tolosa E.

Front Immunol. 2017 Nov 13;8:1505. doi: 10.3389/fimmu.2017.01505. eCollection 2017.

6.

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer.

Prieske K, Prieske S, Joosse SA, Trillsch F, Grimm D, Burandt E, Mahner S, Schmalfeldt B, Milde-Langosch K, Oliveira-Ferrer L, Woelber L.

Oncotarget. 2017 Sep 15;8(47):83063-83074. doi: 10.18632/oncotarget.20945. eCollection 2017 Oct 10.

7.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.

Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou ES.

Clin Chem. 2018 Feb;64(2):297-306. doi: 10.1373/clinchem.2017.275503. Epub 2017 Nov 9.

PMID:
29122836
8.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

9.

Chronic UVB-irradiation actuates perpetuated dermal matrix remodeling in female mice: Protective role of estrogen.

Röck K, Joosse SA, Müller J, Heinisch N, Fuchs N, Meusch M, Zipper P, Reifenberger J, Pantel K, Fischer JW.

Sci Rep. 2016 Jul 27;6:30482. doi: 10.1038/srep30482.

10.

Comparative study of whole genome amplification and next generation sequencing performance of single cancer cells.

Babayan A, Alawi M, Gormley M, Müller V, Wikman H, McMullin RP, Smirnov DA, Li W, Geffken M, Pantel K, Joosse SA.

Oncotarget. 2016 Jul 19;8(34):56066-56080. doi: 10.18632/oncotarget.10701. eCollection 2017 Aug 22.

11.

Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®.

Gorges TM, Stein A, Quidde J, Hauch S, Röck K, Riethdorf S, Joosse SA, Pantel K.

PLoS One. 2016 May 16;11(5):e0155126. doi: 10.1371/journal.pone.0155126. eCollection 2016.

12.

Genetic traits for hematogeneous tumor cell dissemination in cancer patients.

Joosse SA, Pantel K.

Cancer Metastasis Rev. 2016 Mar;35(1):41-8. doi: 10.1007/s10555-016-9611-7. Review.

PMID:
26931653
13.

Enumeration and Molecular Characterization of Tumor Cells in Lung Cancer Patients Using a Novel In Vivo Device for Capturing Circulating Tumor Cells.

Gorges TM, Penkalla N, Schalk T, Joosse SA, Riethdorf S, Tucholski J, Lücke K, Wikman H, Jackson S, Brychta N, von Ahsen O, Schumann C, Krahn T, Pantel K.

Clin Cancer Res. 2016 May 1;22(9):2197-206. doi: 10.1158/1078-0432.CCR-15-1416. Epub 2015 Dec 14.

14.

Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients.

Joosse SA, Pantel K.

Cancer Cell. 2015 Nov 9;28(5):552-554. doi: 10.1016/j.ccell.2015.10.007.

15.

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients.

Meng X, Joosse SA, Müller V, Trillsch F, Milde-Langosch K, Mahner S, Geffken M, Pantel K, Schwarzenbach H.

Br J Cancer. 2015 Nov 3;113(9):1358-66. doi: 10.1038/bjc.2015.340. Epub 2015 Sep 22.

16.

High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Parplys AC, Seelbach JI, Becker S, Behr M, Wrona A, Jend C, Mansour WY, Joosse SA, Stuerzbecher HW, Pospiech H, Petersen C, Dikomey E, Borgmann K.

Cell Cycle. 2015;14(19):3190-202. doi: 10.1080/15384101.2015.1055996.

17.

Biology, detection, and clinical implications of circulating tumor cells.

Joosse SA, Gorges TM, Pantel K.

EMBO Mol Med. 2015 Jan;7(1):1-11. doi: 10.15252/emmm.201303698. Review.

18.

Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and miR-202 in the blood of patients with breast cancer and benign breast diseases.

Joosse SA, Müller V, Steinbach B, Pantel K, Schwarzenbach H.

Br J Cancer. 2014 Aug 26;111(5):909-17. doi: 10.1038/bjc.2014.360. Epub 2014 Jul 1.

19.

Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.

Babayan A, Hannemann J, Spötter J, Müller V, Pantel K, Joosse SA.

PLoS One. 2013 Sep 18;8(9):e75038. doi: 10.1371/journal.pone.0075038. eCollection 2013.

20.

Biologic challenges in the detection of circulating tumor cells.

Joosse SA, Pantel K.

Cancer Res. 2013 Jan 1;73(1):8-11. doi: 10.1158/0008-5472.CAN-12-3422. Epub 2012 Dec 27. Review.

21.

BRCA1 and BRCA2: a common pathway of genome protection but different breast cancer subtypes.

Joosse SA.

Nat Rev Cancer. 2012 May 24;12(5):372; author reply 372. doi: 10.1038/nrc3181-c2. No abstract available.

PMID:
22525577
22.

Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells.

Joosse SA, Hannemann J, Spötter J, Bauche A, Andreas A, Müller V, Pantel K.

Clin Cancer Res. 2012 Feb 15;18(4):993-1003. doi: 10.1158/1078-0432.CCR-11-2100. Epub 2012 Jan 6.

23.

Quantitative high-resolution genomic analysis of single cancer cells.

Hannemann J, Meyer-Staeckling S, Kemming D, Alpers I, Joosse SA, Pospisil H, Kurtz S, Görndt J, Püschel K, Riethdorf S, Pantel K, Brandt B.

PLoS One. 2011;6(11):e26362. doi: 10.1371/journal.pone.0026362. Epub 2011 Nov 30.

24.

A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients.

Didraga MA, van Beers EH, Joosse SA, Brandwijk KI, Oldenburg RA, Wessels LF, Hogervorst FB, Ligtenberg MJ, Hoogerbrugge N, Verhoef S, Devilee P, Nederlof PM.

Breast Cancer Res Treat. 2011 Nov;130(2):425-36. doi: 10.1007/s10549-011-1357-x. Epub 2011 Feb 1.

PMID:
21286804
25.

Specific genomic aberrations in primary colorectal cancer are associated with liver metastases.

Bruin SC, Klijn C, Liefers GJ, Braaf LM, Joosse SA, van Beers EH, Verwaal VJ, Morreau H, Wessels LF, van Velthuysen ML, Tollenaar RA, Van't Veer LJ.

BMC Cancer. 2010 Dec 2;10:662. doi: 10.1186/1471-2407-10-662.

26.

Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.

Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM.

Genes Chromosomes Cancer. 2011 Feb;50(2):71-81. doi: 10.1002/gcc.20833.

PMID:
21104783
27.

Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.

Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J.

BMC Cancer. 2010 Aug 24;10:455. doi: 10.1186/1471-2407-10-455.

28.

Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM.

Breast Cancer Res Treat. 2012 Apr;132(2):379-89. doi: 10.1007/s10549-010-1016-7. Epub 2010 Jul 8.

PMID:
20614180
29.

Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients.

Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders MJ, Wessels LF, van de Vijver MJ.

Clin Cancer Res. 2010 Jan 15;16(2):651-63. doi: 10.1158/1078-0432.CCR-09-0709. Epub 2010 Jan 12.

30.

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM.

Breast Cancer Res. 2009;11(4):R63. doi: 10.1186/bcr2354. Epub 2009 Aug 26.

31.

Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality.

van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Brüggenwirth HT, Withagen-Hermans CJ, Collée JM, Joosse SA, Terlouw-Kromosoeto JN, Nederlof PM.

Genet Test Mol Biomarkers. 2009 Jun;13(3):399-406. doi: 10.1089/gtmb.2008.0155.

PMID:
19405878
32.

Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer.

Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, Joosse SA, Vahteristo P, Kiuru M, Karhu A, Sammalkorpi H, Vanharanta S, Lehtonen R, Edgren H, Nederlof PM, Hietala M, Aittomäki K, Herva R, Knuutila S, Aaltonen LA, Launonen V.

Genes Chromosomes Cancer. 2009 Jul;48(7):544-51. doi: 10.1002/gcc.20663.

PMID:
19373782
33.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.

34.

Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.

Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM.

Breast Cancer Res Treat. 2009 Aug;116(3):479-89. doi: 10.1007/s10549-008-0117-z. Epub 2008 Aug 14.

PMID:
18704682
35.

ESR1 gene amplification in breast cancer: a common phenomenon?

Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ.

Nat Genet. 2008 Jul;40(7):807-8; author reply 810-2. doi: 10.1038/ng0708-807. No abstract available.

PMID:
18583965
36.

Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA; kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD.

Eur J Hum Genet. 2008 Jul;16(7):820-32. doi: 10.1038/ejhg.2008.13. Epub 2008 Feb 20.

37.
38.

A multiplex PCR predictor for aCGH success of FFPE samples.

van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, Nederlof PM.

Br J Cancer. 2006 Jan 30;94(2):333-7.

Supplemental Content

Loading ...
Support Center